ÁTÁngel Cristóbal Santacruz Tipanta

Ángel Cristóbal Santacruz Tipanta

*This is an algorithmically generated author record based on publicly available information.

Ángel Cristóbal Santacruz Tipanta has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Blood pressure control with active ultrafiltration measures and without antihypertensives is essential for survival in hemodiafiltration and hemodialysis programs for patients with CKD: a prospective observational study

    by Franklin Geovany Mora-Bravo, Pamela Tatiana Morales Torres, Nelson Rojas Campoverde, Guillermina Lucía Blum Carcelen, Juan Cristobal Santacruz Mancheno, Ángel Cristóbal Santacruz Tipanta, Hector Perez-Grovas, Willan Patricio Robles Abarca

    Background: High blood pressure is a prevalent condition in patients with chronic kidney disease on hemodialysis. Adequate control of high blood pressure is essential to reducing deaths in this group. The present study aimed to observe mortality prospectively in a group of patients in hemodialysis and hemodiafiltration programs in whom the use of antihypertensives was optimized with the point-of-care dry weight (POC-DW) technique. Methods: The present observational, prospective study was carried out at the Pafram hemodiafiltration unit in Morona Santiago, Ecuador, and the hemodialysis unit of the Fundación Renal del Ecuador in Guayaquil, Ecuador, from August 2019 to December 2023. Patients who were receiving hemodiafiltration were included. Weight was optimized with POC-DW for eight weeks. In Group 1, patients whose use of antihypertensive drugs was not required to control systolic blood pressure with a value less than 150 mmHg predialysis, less than 130 mmHg postdialysis, and a peridialytic blood pressure (defined as post-HD minus pre-HD SBP) between 0 and − 20 mmHg were analyzed. In Group 2, patients who required antihypertensive drugs for not meeting the aims of systolic blood pressure were included. The variables included clinical, demographic, mortality, description of the treatment, and routine laboratory tests in dialysis programs. The sample was nonprobabilistic. Survival analysis was performed for the study groups. The log-rank test (Mantel-Cox) was used for survival comparisons. Results: The study included 106 patients. Optimal blood pressure control without antihypertensive treatment was achieved in 52 patients (49.1%) (Group 1). In 54 patients (50.9%), antihypertensive agents were required (Group 2). There was more significant mortality in the group that received antihypertensives: 11 patients in group 1 (21.2%) versus 25 patients in group 2 (46.3%) (P = 0.005). Survival was more significant in group 1, with an HR of 2.2163 (1.125–4.158) (P = 0.0243). Conclusion: In hemodiafiltration and hemodialysis programs, blood pressure control with active ultrafiltration measures and without using antihypertensives is essential for survival in patients with CKD.


  • Open Access

    Falsa positivización del antígeno de superficie del virus de la Hepatitis B (HBsAg) tras vacunación.

    by Juan Cristobal Santacruz Mancheno, Layla Báez, Paulo Reinoso, Paola Arévalo, Nairi Sucre, Gabriela Santacruz Mancheno, Cristobal Santacruz Tipanta

    Introduction: The chronic hemodialysis population has a greater exposure and risk to the hepatitis B virus, which is why immunoprophylaxis using the double dose scheme (40mcg) on days 0-30-60-180, with application of this regimen for a second extra time in nonresponders, is common practice in this population. Clinical case: This is a 67-year-old male patient of Afro-Ecuatorian ethnicity who started hemodialysis (HD) in August 2023 for chronic kidney disease (CKD) secondary to diabetic nephropathy. When starting HD, he had negative serology for hepatitis and negativity for HBsAg. For this reason, he received his first vaccination dose on November 29, 2023, and on December 15, he had HBsAg positivity with values of 4.14 S/CO (≥1 positive), with Ac-ANTI-HBSAG levels < 2 IU/L. Management: Given the findings, it was decided to isolate the patient with control of liver function, which is normal, and a new test of HBsAg levels in 15 days, which were subsequently negative. Conclusion: In this case, we want to remember the false politicization of HBsAg after vaccination in hemodialysis patients, a situation associated with the vaccine being composed of live attenuated viruses or recombinant particles of surface proteins.

  • Global Dialysis Perspectives: Ecuador

    by Juan Santacruz Mancheno, Angel Cristóbal Santacruz

    This is an Early Access article. Please select the PDF button, above, to view it.